Drug Topics
MARCH 30, 2025
Tom DePietro, PharmD, owner of DePietro's Pharmacy, highlights the deep community connections that enabled the pharmacy to respond effectively to the pandemic.
Pharmacy Times
MARCH 30, 2025
The trial is the first to test the cardiovascular benefits of an oral glucagon-like peptide-1 (GLP-1) agonist.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Healthcare
MARCH 30, 2025
The federal government has turned its focus to monitoring the billing practices of remote physiologic monitoring and remote therapeutic monitoring over the last two years. Health systems have followed suit.
Pharmacy Times
MARCH 30, 2025
John Buse, MD, PhD discusses the expanding role of GLP-1 receptor agonists in treatment of cardiovascular conditions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The Happy PharmD
MARCH 30, 2025
If you think your patients arent looking at online pharmacies for cheaper medications, youre kidding yourself. Medicine is expensiveeverything is expensive. And when people are desperate, they look for alternatives. The problem? 96% of online pharmacies are illegal. Theyre selling unregulated, potentially dangerous medications, and most patients have no idea.
Pharmacy Times
MARCH 30, 2025
Jawad Butt, MD, offers insight into his analysis of the FINEARTS-HF trial.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
MARCH 30, 2025
Patients in the treatment group had a 21% lower risk of cardiovascular death or first heart failure hospitalization overall, but the between-group difference did not meet the threshold for statistical significance for this primary end point.
Med Ed 101
MARCH 30, 2025
In this case scenario, we outline a situation of risperidone causing tardive dyskinesia. Tardive dyskinesia is a neurological movement disorder that is typically caused by medications that can block dopamine receptors. Antipsychotics are the most commonly used class of medication that block dopamine receptors (great board exam question). ME is a 55-year-old male who has […] The post Risperidone Causing Tardive Dyskinesia – Case Sceniaro appeared first on Med Ed 101.
STAT
MARCH 30, 2025
Robert F. Kennedy Jr. forcing Peter Marks out of the Food and Drug Administration has blown a hole in the agency’s leadership ranks and threatens to unmoor the oversight of drugs and vaccines from bedrock scientific principles. For biotech investors, Marks’ ouster is a worst-case scenario realized — an FDA riven by dysfunction and uncertainty.
Expert insights. Personalized for you.
247 
Let's personalize your content